Galapagos Conference call feedback: Business split creates freedom for Galapagos
Yesterday, Galapagos announced that the company will be split into 2 public entities being i) Galapagos (GLPG 2.0), which will solely focus on the cell therapy program while gaining freedom from the Gilead agreement, and ii) SpinCo, with new management and € 2.45b to develop a new pipeline using BD in collaboration with Gilead. Below we provide our key takeaways from the conference call and our 1-1 interaction with management.Galapagos is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action, addressing disease areas of high unmet medical need. Execution on its proprietary drug target discovery platform has delivered a pipeline that consists of three Phase 2, three Phase 1, five pre-clinical, and 20 discovery programs in inflammation, cystic fibrosis, or CF, osteoarthritis, and other indications. Co.'s highly flexible platform offers applicability across a broad set of therapeutic areas. Co.'s programs include filgotinib, GLPG1837, GLPG1690, GLPG2222, GLPG1972.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.